CA
NZ
UK
AU
IND
US
Altimmune (NASDAQ:ALT) rose 0.3% to $3.05 in pre-market trading as the obesity and liver disease developer prepares for the Stifel Cardiometabolic Forum. About 27% of the float is sold short with 15.4 days to cover, among the longest cover times of any heavily shorted …
Novo Nordisk A/S has told investors to expect its first sales and profit decline in years, guiding to a 2026 sales range implying a drop of 5 to 13 percent. Shares fell roughly 12 percent on the initial warning, part of a string of …
Pfizer Inc. has completed its acquisition of Metsera, Inc., a deal that ultimately valued the obesity-focused biotech at roughly USD 10 billion after a competitive bidding process that saw Pfizer's offer rise from an initial proposal near USD 4.9 billion. The acquisition was framed …
UnitedHealth Group Incorporated has confirmed it is cooperating with a Department of Justice investigation into how it bills Medicare for its Medicare Advantage plans, an inquiry first disclosed in mid-2025. Since then, reporting has indicated the criminal probe has broadened considerably, extending to UnitedHealth's …
CVS Health Corp. shares advanced afterSell-Sideanalysts pointed to the company's expanding oncology care initiative as a credible new growth lever. Coverage has referenced an Overweight rating alongside upwardly revised price targets, framing the oncology push as complementary to CVS Health's broader turnaround, which has …
Eli Lilly and Company posted second-quarter 2026 revenue of USD 23 billion, a 48 percent increase from the prior-year period and well ahead of the roughly USD 20.6 billionWall Streethad modeled. The growth was concentrated in the company's tirzepatide franchise, sold as Mounjaro for …
Moderna's melanomaVaccineprogram has moved from a promising mid-stage signal to a confirmed late-stage result. The original Phase 2b KEYNOTE-942 study, run with Merck & Co., Inc. , showed the personalized mRNA vaccine mRNA-4157, now known as intismeran autogene, reduced the risk of recurrence or …
Prime Medicine (NASDAQ:PRME) shares are up 10.10% pre-market to $3.38, building on a prior close of $3.07, after the FDA cleared the company's Investigational New Drug application for PM647, an in vivo gene-editing therapy targeting Alpha-1 Antitrypsin Deficiency (AATD). The clearance allows the therapy, …
10x Genomics (NASDAQ:TXG) shares are up 2.87% pre-market to $86.52, building on last week's roughly 7-12% surge, as investors continue to digest a legal patent win, strong early demand for the company's new Atera platform, and momentum from raised full-year 2026 revenue guidance of …
Addex Therapeutics (NASDAQ:ADXN) shares are up 10.69% pre-market to $3.83, building on a prior close of $3.46, after the company announced it has regained full global rights to all GABAB positive allosteric modulator assets discovered under its research collaboration with Indivior. The reversion follows …
Please wait processing your request...